Table III.
Subgroup analyses for effect of GP73 on HCC overall survival
| Parameter | N of studies | Effect model | HR (95% CI) | P-value | Heterogeneity test | |
|---|---|---|---|---|---|---|
| I2 (%) | P-value | |||||
| Overall | 9 | Random | 1.61 (1.15–2.27) | 0.006 | 63 | 0.01 |
| Sample size: | ||||||
| < 90 | 3 | Random | 1.47 (0.85–2.51) | 0.17 | 87 | < 0.001 |
| ≥ 90 | 6 | Fixed | 1.84 (1.54–2.19) | < 0.001 | 0 | 0.86 |
| Duration of follow-up [months]: | ||||||
| < 60 | 5 | Random | 1.51 (0.83–2.78) | 0.18 | 76 | 0.002 |
| ≥ 60 | 4 | Fixed | 1.85 (1.49–2.30) | < 0.001 | 0 | 0.65 |
CI – confidence interval, GP73 – Golgi protein 73, HCC – hepatocellular carcinoma, HR – hazard ratio, N – number.